Market Closed -
Nasdaq
16:00:00 2024-05-09 EDT
|
5-day change
|
1st Jan Change
|
6.25
USD
|
-7.27%
|
|
-10.07%
|
-5.30%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
92.65
|
266.4
|
446.3
|
110.9
|
185
|
409.2
|
-
|
-
|
Enterprise Value (EV)
1 |
92.65
|
266.4
|
446.3
|
110.9
|
185
|
409.2
|
409.2
|
409.2
|
P/E ratio
|
-2.74
x
|
-6.93
x
|
-8.39
x
|
-2.3
x
|
-5.15
x
|
-8.67
x
|
-6.53
x
|
-5.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
67.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
67.7
x
|
EV / EBITDA
|
-5,533,500
x
|
-8,705,617
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-13.9
x
|
-2.97
x
|
-6.3
x
|
-7.81
x
|
-3.76
x
|
-2.56
x
|
FCF Yield
|
-
|
-
|
-7.2%
|
-33.7%
|
-15.9%
|
-12.8%
|
-26.6%
|
-39.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,762
|
29,009
|
43,984
|
44,073
|
44,101
|
44,238
|
-
|
-
|
Reference price
2 |
4.463
|
9.182
|
10.15
|
2.516
|
4.195
|
9.249
|
9.249
|
9.249
|
Announcement Date
|
19-12-19
|
20-12-15
|
21-11-18
|
22-12-13
|
23-12-12
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6.04
|
EBITDA
|
-16.74
|
-30.6
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.77
|
-30.74
|
-46.8
|
-50.52
|
-43.61
|
-54.32
|
-79.98
|
-112.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,860.44%
|
Earnings before Tax (EBT)
1 |
-13.66
|
-30.22
|
-46.42
|
-48.13
|
-36.07
|
-47.46
|
-72.88
|
-101.4
|
Net income
1 |
-13.71
|
-29.85
|
-46.37
|
-47.98
|
-36.08
|
-47.46
|
-72.88
|
-101.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,678.56%
|
EPS
2 |
-1.628
|
-1.324
|
-1.210
|
-1.093
|
-0.8143
|
-1.067
|
-1.416
|
-1.804
|
Free Cash Flow
1 |
-
|
-
|
-32.11
|
-37.35
|
-29.36
|
-52.41
|
-108.9
|
-159.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,647.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-12-19
|
20-12-15
|
21-11-18
|
22-12-13
|
23-12-12
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.61
|
-11.53
|
-14.9
|
-11.95
|
-9.733
|
-10.57
|
-10.97
|
-11.92
|
-9.701
|
-10.21
|
-12.59
|
-14.49
|
-16.98
|
-25.76
|
-29.83
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.74
|
-11.54
|
-14.1
|
-11.41
|
-8.734
|
-9.063
|
-9.428
|
-9.765
|
-7.438
|
-8.015
|
-11.21
|
-12.88
|
-15.31
|
-25.76
|
-29.83
|
Net income
1 |
-10.74
|
-11.54
|
-14.1
|
-11.35
|
-8.643
|
-9.059
|
-9.43
|
-9.765
|
-7.441
|
-8.015
|
-11.21
|
-12.88
|
-15.31
|
-25.76
|
-29.83
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2520
|
-0.2665
|
-0.3247
|
-0.2571
|
-0.1914
|
-0.2017
|
-0.2137
|
-0.2274
|
-0.1628
|
-0.1882
|
-0.2544
|
-0.2896
|
-0.3330
|
-0.5690
|
-0.6640
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-18
|
22-02-03
|
22-05-10
|
22-08-04
|
22-12-13
|
23-02-07
|
23-05-09
|
23-08-08
|
23-12-12
|
24-02-13
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-32.1
|
-37.3
|
-29.4
|
-52.4
|
-109
|
-160
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-12-19
|
20-12-15
|
21-11-18
|
22-12-13
|
23-12-12
|
-
|
-
|
-
|
Last Close Price
9.249
CAD Average target price
26.63
CAD Spread / Average Target +187.95% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.30% | 298M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|